The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Uma Sundram - One of the best experts on this subject based on the ideXlab platform.

  • immunophenotypic analysis of myeloperoxidase negative Leukemia Cutis and blastic plasmacytoid dendritic cell neoplasm
    American Journal of Clinical Pathology, 2012
    Co-Authors: Danielle M P Cronin, Tracy I George, Kaaren K Reichard, Uma Sundram
    Abstract:

    Myeloid Leukemia Cutis (LC) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are morphologically indistinguishable malignancies that frequently manifest in the skin. Separating myeloperoxidase-negative LC from BPDCN may be particularly challenging. We identified a panel of immunohistochemical stains to distinguish myeloid LC (23 cases) from BPDCN (12 cases): myeloperoxidase, which stained 7 cases (30%) of LC and 0 cases (0%) of BPDCN; CD56, which stained 12 cases (52%) of LC and all 12 cases (100%) of BPDCN; CD4, which stained 2 cases (9%) of LC and all 12 cases (100%) of BPDCN; CD123, which stained 4 cases (17%) of LC and 10 cases (83%) of BPDCN; and Tcl-1, which stained 2 cases (9%) of LC and 9 (82%) of 11 cases of BPDCN. It is interesting that CD33 was not helpful; it stained 18 (78%) cases of LC and 11 cases (92%) of BPDCN. Our results indicate that a panel that includes CD4, CD56, CD123, and Tcl-1 can appropriately distinguish between these 2 entities.

  • an updated approach to the diagnosis of myeloid Leukemia Cutis
    American Journal of Clinical Pathology, 2009
    Co-Authors: Danielle M P Cronin, Tracy I George, Uma Sundram
    Abstract:

    The diagnosis of myeloid Leukemia Cutis can be difficult, particularly in the context of an initial skin biopsy with a malignant hematopoietic neoplasm. We studied the immunohistochemical characteristics of 33 cases of myeloid Leukemia Cutis diagnosed at Stanford University Medical Center, Stanford, CA, 1996-2007, and compared them with the corresponding bone marrow blast immunophenotype and World Health Organization classification (2008). In the skin, CD43 marked 97% of cases (32/33), myeloperoxidase marked 42% (14/33), CD68 marked 94% (31/33), CD163 marked 25% (7/28), and CD56 marked 47% (14/30). CD34 and CD117 were predominantly negative. In 19 cases in which myeloperoxidase was negative, all marked with CD68 and CD43. The flow cytometric immunophenotype of the leukemic blasts in the bone marrow was discordant with the immunohistochemical profile in the skin in all cases, showing loss or gain of at least 1 antigen. Given the immunophenotypic differences between skin and bone marrow blasts, we provide an updated immunohistochemical approach to the diagnosis of myeloid Leukemia Cutis.

  • mast cell tryptase and microphthalmia transcription factor effectively discriminate between cutaneous mast cell disorders and Leukemia Cutis a comparative cytochemical and immunohistochemical study
    Journal of Cutaneous Pathology, 2008
    Co-Authors: Uma Sundram, Yasodha Natkunam
    Abstract:

    Cutaneous mast cell disorders are uncommon but a subset of these disorders, especially mastocytoma, can histologically mimic Leukemia Cutis. Our objective was to employ a panel of cytochemical and immunohistolochemical markers to determine which markers would be most useful in distinguishing these entities. We studied 17 cases of cutaneous mast cell disorders (UP, TMEP, and mastocytoma) and 12 cases of Leukemia Cutis (myeloid, myelomonocytic and monocytic) with toluidine blue, Giemsa, pinacyanol erythrocyanate (PE), mast cell tryptase, microphthalmia transcription factor (MITF), CD117, myeloperoxidase, CD43 and CD68. We found that PE stained the majority of cases of mast cell disorders (11/15) but did not stain Leukemia Cutis. Tryptase and MITF stained all cases of mast cell disorders but not Leukemia Cutis. Although CD117 showed strong staining in all cases of mast cell disorders, it also stained up to 25% of cases of Leukemia Cutis (2/8). Staining for myeloperoxidase was specific to Leukemia Cutis but detected only Leukemias with myeloid differentiation (6/12). Our results show that mast cell tryptase and microphthalmia transcription factor are equally effective in distinguishing mast cell disorders from Leukemia Cutis. Interestingly, pinacyanol erythrocyanate appears to be specific for mast cell disease, as no staining was seen in Leukemia Cutis.

  • mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid Leukemia Cutis
    Journal of Cutaneous Pathology, 2007
    Co-Authors: Uma Sundram, Yasodha Natkunam
    Abstract:

    Background:  Cutaneous mast cell disorders are uncommon, but a subset, especially mastocytoma and mast cell Leukemia, can histologically mimic myeloid Leukemia Cutis. Our objective was to employ a panel of cytochemical and immunohistochemical markers to determine which ones would be most useful in separating these two entities. Methods:  We stained 17 cases of cutaneous mast cell disease and 20 cases of myeloid Leukemia Cutis with Giemsa, toluidine blue, or pinacyanol erythrosinate (PE), as well as with antibodies against mast cell tryptase, microphthalmia transcription factor (MiTF), CD117 (c-kit), myeloperoxidase, CD43, CD25, CD2, and CD68. Results:  Mast cell tryptase and MiTF emerged as highly sensitive and specific markers for mast cell disease in this context, as both antibodies stained all cases of mast cell diseases but none of myeloid Leukemia Cutis. Although CD117 stained all cases of mast cell disease, it also stained 2 of 18 cases of myeloid Leukemia Cutis. PE appeared to be specific for mast cell disease, as 11 of 12 cases stained with this marker, compared with 0 of 18 cases of myeloid Leukemia Cutis. Conclusions:  Our results show that mast cell tryptase and MiTF are equally effective in distinguishing mast cell disease from myeloid Leukemia Cutis.

Hans Theodor Eich - One of the best experts on this subject based on the ideXlab platform.

  • the effectiveness of radiotherapy for Leukemia Cutis
    Journal of Cancer Research and Clinical Oncology, 2017
    Co-Authors: Khaled Elsayad, Michael Oertel, Uwe Haverkamp, Hans Theodor Eich
    Abstract:

    Leukemia Cutis (LC) is a rare clinical presentation of Leukemia that is associated with poor prognosisabs. To date, the value of radiotherapy (RT) for the treatment of LC remains controversial. Therefore, the aim of this study was to analyse the effectiveness of various RT doses for LC. Between January 2000 and January 2016, 13 patients underwent RT at our institution after exhibiting progressive disease following other treatment modalities. A total of 36 radiation courses were administered to 13 patients (8 females, 5 males) with a median age of 41 years (range 2–76). Radiation modalities included 32 focal treatments, while total skin electron beam therapy was applied to four patients. The median RT dose was 27 Gy (range 8–34). A complete response rate (CRR) to RT was achieved for 32/36 (89%) lesions (100% for AML lesions versus 33% for the other Leukemias; P  26 Gy) versus low-dose regimens (≤26 Gy) was 95 versus 83%, respectively (P = 0.26), and the median DOLC was 44 months versus 10 months, respectively (P = 0.019). AML patients had a better long-term outcome than the other patients according to median DOLC (40 months versus 2 months, respectively; P  26 Gy were associated with a longer DOLC. LC patients with underlying AML are associated with better outcome compared with other types of Leukemia.

Yasodha Natkunam - One of the best experts on this subject based on the ideXlab platform.

  • mast cell tryptase and microphthalmia transcription factor effectively discriminate between cutaneous mast cell disorders and Leukemia Cutis a comparative cytochemical and immunohistochemical study
    Journal of Cutaneous Pathology, 2008
    Co-Authors: Uma Sundram, Yasodha Natkunam
    Abstract:

    Cutaneous mast cell disorders are uncommon but a subset of these disorders, especially mastocytoma, can histologically mimic Leukemia Cutis. Our objective was to employ a panel of cytochemical and immunohistolochemical markers to determine which markers would be most useful in distinguishing these entities. We studied 17 cases of cutaneous mast cell disorders (UP, TMEP, and mastocytoma) and 12 cases of Leukemia Cutis (myeloid, myelomonocytic and monocytic) with toluidine blue, Giemsa, pinacyanol erythrocyanate (PE), mast cell tryptase, microphthalmia transcription factor (MITF), CD117, myeloperoxidase, CD43 and CD68. We found that PE stained the majority of cases of mast cell disorders (11/15) but did not stain Leukemia Cutis. Tryptase and MITF stained all cases of mast cell disorders but not Leukemia Cutis. Although CD117 showed strong staining in all cases of mast cell disorders, it also stained up to 25% of cases of Leukemia Cutis (2/8). Staining for myeloperoxidase was specific to Leukemia Cutis but detected only Leukemias with myeloid differentiation (6/12). Our results show that mast cell tryptase and microphthalmia transcription factor are equally effective in distinguishing mast cell disorders from Leukemia Cutis. Interestingly, pinacyanol erythrocyanate appears to be specific for mast cell disease, as no staining was seen in Leukemia Cutis.

  • mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid Leukemia Cutis
    Journal of Cutaneous Pathology, 2007
    Co-Authors: Uma Sundram, Yasodha Natkunam
    Abstract:

    Background:  Cutaneous mast cell disorders are uncommon, but a subset, especially mastocytoma and mast cell Leukemia, can histologically mimic myeloid Leukemia Cutis. Our objective was to employ a panel of cytochemical and immunohistochemical markers to determine which ones would be most useful in separating these two entities. Methods:  We stained 17 cases of cutaneous mast cell disease and 20 cases of myeloid Leukemia Cutis with Giemsa, toluidine blue, or pinacyanol erythrosinate (PE), as well as with antibodies against mast cell tryptase, microphthalmia transcription factor (MiTF), CD117 (c-kit), myeloperoxidase, CD43, CD25, CD2, and CD68. Results:  Mast cell tryptase and MiTF emerged as highly sensitive and specific markers for mast cell disease in this context, as both antibodies stained all cases of mast cell diseases but none of myeloid Leukemia Cutis. Although CD117 stained all cases of mast cell disease, it also stained 2 of 18 cases of myeloid Leukemia Cutis. PE appeared to be specific for mast cell disease, as 11 of 12 cases stained with this marker, compared with 0 of 18 cases of myeloid Leukemia Cutis. Conclusions:  Our results show that mast cell tryptase and MiTF are equally effective in distinguishing mast cell disease from myeloid Leukemia Cutis.

Khaled Elsayad - One of the best experts on this subject based on the ideXlab platform.

  • the effectiveness of radiotherapy for Leukemia Cutis
    Journal of Cancer Research and Clinical Oncology, 2017
    Co-Authors: Khaled Elsayad, Michael Oertel, Uwe Haverkamp, Hans Theodor Eich
    Abstract:

    Leukemia Cutis (LC) is a rare clinical presentation of Leukemia that is associated with poor prognosisabs. To date, the value of radiotherapy (RT) for the treatment of LC remains controversial. Therefore, the aim of this study was to analyse the effectiveness of various RT doses for LC. Between January 2000 and January 2016, 13 patients underwent RT at our institution after exhibiting progressive disease following other treatment modalities. A total of 36 radiation courses were administered to 13 patients (8 females, 5 males) with a median age of 41 years (range 2–76). Radiation modalities included 32 focal treatments, while total skin electron beam therapy was applied to four patients. The median RT dose was 27 Gy (range 8–34). A complete response rate (CRR) to RT was achieved for 32/36 (89%) lesions (100% for AML lesions versus 33% for the other Leukemias; P  26 Gy) versus low-dose regimens (≤26 Gy) was 95 versus 83%, respectively (P = 0.26), and the median DOLC was 44 months versus 10 months, respectively (P = 0.019). AML patients had a better long-term outcome than the other patients according to median DOLC (40 months versus 2 months, respectively; P  26 Gy were associated with a longer DOLC. LC patients with underlying AML are associated with better outcome compared with other types of Leukemia.

Chansik Park - One of the best experts on this subject based on the ideXlab platform.